- I am doing some housekeeping on the ADLR research page. ADLR stock has been on a tremendous run lately, thanks to upcoming phase 2 data as well as recent comments by the CEO hinting at M&A activity following that event and the recent reacquisition of Entereg rights from GSK.
- See below the jump for notes from a couple more webcasts that did not make it into the blog on the first go-around- 4/6/11 Needham conference and 4/28/11 1q2011 earnings conference call
0 Comments
Edit 7/2011: Check the Past Events page for more information on the American Society of Colon and Rectal Surgeons (ASCRS) meeting to be held May 14-18, 2011 in Vancouver, Canada.
-ADLR presented three abstracts on Entereg (alvimopan) - full text details below the jump ADLR presented at the Cowen conference on 3/7/11. The slide deck was revised from what I have seen previously and I thought the presentation was better than most. I will update the ADLR research page shortly with relevant changes, as well as upload a few screenshots of interesting slides from the talk. Here are my quick notes:
ADLR announced 4q2010 results yesterday morning 2/23/10 and held a brief conference call for investors. Here are the salient notes:
First, here is the earnings press release link I also have updated the ADLR research page at this link Year end cash balance was $46.6m, burned $36.6m cash in 2010 Entereg Notes
|
Categories
All
Archives
January 2020
|